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Abstract
Background: To estimate the proportion of diabetic patients (DPts) with peripheral vascular
disease treated at a primary health care site after an endocrinologist-based intervention, who meet
ATP III and Steno targets of metabolic control, as well as to compare the outcome with the results
of the patients treated by endocrinologists.
Methods: A controlled, prospective over 30-months period study was conducted in area 7 of
Madrid. One hundred twenty six eligible diabetic patients diagnosed as having peripheral vascular
disease between January 2003 and June 2004 were included in the study. After a treatment period
of three months by the Diabetes team at St Carlos Hospital, 63 patients were randomly assigned
to continue their follow up by diabetes team (Group A) and other 63 to be treated by the family
physicians (FP) at primary care level with continuous diabetes team coordination (Group B). 57
DPts from Group A and 59 from Group B, completed the 30 months follow-up period. At baseline
both groups were similar in age, weight, time from diagnosis and metabolic control. The main
outcomes of this study were the proportion of patients meeting ATP III and Steno goals for HbA1c
(%), Cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, blood pressure, albumine-to-
creatinine excretion ratio (ACR), body mass index (BMI), waist circumference (WC), anti-
aggregation treatment and smoking status.
Results: At the end of the follow up, no differences were found between the groups. More than
37% of diabetic patients assigned to be treated by FP achieved a HbA1c < 6.5%, more than 50% a
ACR < 30 mg/g, and more than 80% reached low risk values for cholesterol, LDL cholesterol,
triglycerides, diastolic blood pressure and were anti-aggregated, and 12% remained smokers. In
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contrast, less than 45% achieved a systolic blood pressure < 130 mm Hg, less than 12% had a BMI
< 25 Kg.m-2 (versus 23% in group A; p < 0.05) and 49%/30% (men/women) had a waist
circumference of low risk.
Conclusion: Improvements in metabolic control among diabetic patients with peripheral vascular
disease treated at a primary health care setting is possible, reaching similar results to the patients
treated at a specialized level. Despite such an improvement, body weight control remains more
than poor in both levels, mainly at primary care level. General practitioner and endocrinologist
coordination care may be important to enhance diabetes management in primary care settings.
Trial registration: Clinical Trial number ISRCTN75037597
Background
Cardiovascular morbidity is a major burden in subjects
with type 2 diabetes mellitus. The estimated risk of death
is two to six times fold compared with the non-diabetic
population. Intensive treatment of multiple modifiable
risk factors including hyperglycemia, hypertension, dysli-
pidemia, obesity, waist perimeter, physical inactivity and
smoking reduces micro and macrovascular events [1-3].
Data from the Steno 2 study [3] show that a multifactorial
intervention involving multiple risk factors significantly
reduces the risk of both cardiovascular and microvascular
events. However, other approaches are possible. Patients
assigned to conventional treatment were treated by their
general physicians (GP). Meanwhile these assigned to the
intensive group were followed up by a specialized team at
the Steno Diabetes Centre. Glycemic targets during last
period of follow-up were similar in both groups. Despite
suboptimal glycemic control in both groups, GPs were
unable to achieve low-risk values in a similar percentage
of patients as the specialized centre, indicating scope for
diabetes management at primary care level to be
improved. Inadequate glycemic and modifiable risk fac-
tors control are due both to patient non adherence, and to
the failure of providers to initiate or intensify the therapy
appropriately [4-8]. In addition, GP care without well
developed support for family doctors was associated with
adverse outcomes for diabetic patients. In shared care
schemes featuring more intensive support there was no
difference in mortality between care in hospital and care
in general practice, glycated haemoglobin tended to be
lower in primary care and losses to follow up were signif-
icantly lower in the primary care setting [9]. Surveys in
Spain revealed that metabolic control of diabetic subjects
treated at primary care level [10-15] was worse than in
diabetes centres [16,17]. These finding suggested that dia-
betes management in primary care level might be
improved if diabetes specialist strategies were imple-
mented by GP.
Since 1993 a foot care programme for people with diabe-
tes and neuropathy is available in Area 7 of Madrid in
order to reduce lower extremity amputations [18-20].
Patients with peripheral vascular disease (PVD) are likely
to be influenced more favourably by surgical procedures
and multifactorial management. We have recently
reported that diabetic subjects with PVD have a poorer
control of modifiable risk factors than diabetic subjects
with other clinical manifestations of cardiovascular dis-
ease [21]. Bearing in mind that most of the type 2 diabetes
patients are treated in a primary care setting, and that a
better metabolic control can reduce their complications, a
reduction in the burden of diabetes mellitus should be
achieved with a more efficient implementation of multi-
factorial management at primary level. In addition, gen-
eral practitioner and endocrinologist coordination should
be the basis for diabetes care.
Since 2003 the Foot Care programme in Area 7 of Madrid
includes also specific strategies to improve the manage-
ment of diabetic patients with PVD by empowering family
physicians (FP) at primary health centres to carry out mul-
tifactorial pharmacologic therapy. Meanwhile a smooth
and continuous contact between FP and endocrinology
service physicians is maintained.
The impact of these interventions on metabolic control of
diabetic patients with PVD treated in a Primary Health
Care Level was prospectively assessed over 30 months and
the outcomes compared with those patients followed by
endocrinologists. In these circumstances we think that FP
may achieve follow up and metabolic control at least as
good as endocrinologists.
Methods
The National Health Service-covering 99% of the total
population- has divided the Madrid Community into 11
health care areas. The public health care system from the
area 7, Madrid, is provided by a single hospital (Hospital
Clinico San Carlos) with a single specialized service for in-
and out-patients with diabetes mellitus (Department of
Endocrinology and Nutrition), and by 22 Primary Health
Care Centres with 304 Family Physicians (FP). According
to 2004 census, the total urban population in this areaBMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
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was 569,307 (261,529 men and 307,778 women). Since
1991, a Diabetes Programme is available in Area 7. Thus,
FP and endocrinologists are coordinated in order to
schedule the diabetes care in the out patient setting. Since
2003, a specific multifactorial intervention (MI) pro-
gramme in type 2 diabetic patients is being carried out. All
FP received yearly orientation about the trial in three days
-8 hours a day-meeting at central level (CAP Espronceda)
with lectures and practical case discussions of MI manage-
ment. Four meeting were carried out between 2003 and
2006. In addition, three 2-hours sessions at each Health
Care Centre were carried out 9 times a year, where FP from
three to seven health care teams joined to physicians from
the endocrinology service to discuss Steno-based algo-
rithms developed by endocrinology and FP leaders of
each Health Care Centre. In total, 216 hours sessions were
carried out between 2003 and 2006. Theses algorithms
were evaluated for clinical acceptability, considering items
such as patient situation, self-monitoring of capillary
blood glucose, laboratory and clinical data. FP also had an
open and continuous communication with endocrinolo-
gists by mail, phone and face to face. In addition, each FP
has a personal endocrinologist assigned for contact. The
main focus of this program is not a single contact, but a
continuous exchange of information between FP and the
diabetes team, to optimize the management of these dia-
betic patients and avoid inertia.
The recommendations for management of hyperglycae-
mia, hypertension and dyslipidemia were based upon the
Steno-2 study and body weight and waist circumference
after ATP-III targets. In addition a stepwise implementa-
tion of pharmacological treatment and behaviour modifi-
cation to achieve low risk cardiovascular values and to
smoke cessation if necessary was applied. In short,
patients were periodically followed, at least every 2 to 4
weeks in the beginning and after each pharmacologic
treatment change, in order to adapt their therapy to the
following objectives: -blood pressure < 130/80 mm Hg, -
LDL cholesterol < 100 mg/dl, -triglycerides < 150 mg/dl, -
HDL cholesterol > 40/50 mg/dl (M/W), -fasting and pre-
prandial capillary glucose values between 70 and 120 mg/
dl -and 2 h-postprandial capillary glucose values between
70 and 135 mg/dl in 60% of the capillary blood glucose
determinations, as well as Hb A1c (DCCT standardized) <
6.5%. Simultaneously, they were antiaggregated (100 mg
aspirin) and a smoking-cessation program was offered.
Nutrition intervention based on Diabetes Nutrition and
Clinical Trial study, DNCT [16,17,22] aimed to achieve
PUFAs/SFAs > 0.4 and MUFAs/SFAs > 1.4. Regular leisure
light-exercise was recommended, namely climbing at least
4 flights of stairs and walking at least 4 blocks 4 times a
day each. In addition, irbesartan 300 mg/day was pre-
scribed when the albumin-to-creatinine ratio > 30 mg/g,
irrespectively of the blood pressure level. After this period,
an individual medical consultation every third month (4
a year) was offered to all patients. Nurse (and medical if
necessary) consultations were always open at patients'
request.
The protocol of type 2 diabetes management and diabetes
and cardiovascular disease treatment was approved by the
Commission of Clinical Guidelines of the St Carlos Uni-
versity Hospital. All patients received treatment according
to these guidelines which are annually revised. An
informed consent was considered not necessary. The
study was conducted according with the Declaration of
Helsinki and with the consort guidelines for clinical trial.
The study was approved by the St Carlos University Hos-
pital Ethic Committee.
Between January 2003 and June 2004, 924 diabetic
patients recruited for the screening foot-care programme
were tested for peripheral vascular disease and selected
when diagnosed. Peripheral vascular disease was consid-
ered when diabetic subjects had at least one diagnostic cri-
teria: -patients who underwent a peripheral vascular
revascularization at least 6 months before, -patients with
previous non-neuropathy foot lesions at least 6 months
before, or -at least one ABI < 0.8. The design of the screen-
ing programme focused on detection of early neuropathy
and the intervention programme based on continuous
well-organized education, and supported by regular podi-
atry assistance for people with diabetes with different
stages of neuropathy, has been previously described else-
where [19,20]. For sample size calculation for the hypoth-
esis that there will be no difference between FP and
specialist care, a primary composite end-point difference
of percentage of diabetic patients with progression of
peripheral vascular disease and mortality during planned
median follow-up period of 60. months has been used.
Sample size adjusted for drop-outs of 120 patients pow-
ered to detect a 20% difference between both groups. For
this planned middle-road 30-months analysis, the sample
size was estimate in two ways. For the hypothesis that
there will be no difference between FP and specialist care
in Steno and ATP III goals, a primary end-point difference
in HbA1c value has been used in order to estimate sample
size. From previous studies (UKPDS, DCCT, Steno) differ-
ences expected in HbA1c levels between control group
and experimental group were about 0.7%, being 10% of
HbA1c baseline values in our study. With 41 subjects in
each group, the study had 90% power at 5% significance
(2-sided) for difference = 0 versus difference = 0.72, to
detect a clinically significance difference (10%) in the
HbA1c value between both FP group and specialist care
group. In addition we estimated sample size for the
hypothesis that there will be no inferior FP treatment in
relation to specialist care. A primary end-point difference
of percentage of diabetic patients achieving HbA1c < 6.5%BMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
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more than 20% has been used. In this case, with 60
patients in each group, the study had 89% power at 5%
significance to detect a clinically significance difference
(20%) to be no inferior FP group versus specialist care
group.
126 eligible diabetic patients were diagnosed as having
peripheral vascular disease. After a treatment period of 3–
6 months in the Diabetes Unit of the St Carlos Hospital,
63 patients were randomly (1:1) assigned to receive treat-
ment from family physicians at primary care level (4 were
lost during the follow-up due to address home change)
and 63 from the diabetes team at the Endocrinology Serv-
ice of the St Carlos Hospital (6 were lost during the fol-
low-up due to address home change). One hundred
sixteen patients, 57 treated by the diabetes team at hospi-
tal (Group A), and 59 treated by FP at primary Health Care
Centre (Group B), completed the 30 months of follow-up
and were analyzed. The structure of the clinical trial is
shown in figure 1, and clinical data of analyzed patients
are displayed in table 1.
Visits at the beginning of the study and every 6 months
until completing a 30 months follow-up period included
a physical exam and laboratory tests. Two nurses were
responsible for these visits. Body weight (barefoot, with
indoor clothes), waist circumference and blood pressure
with adequate sized armlet after 3 minutes in a supine
position were measured. At the same time three consecu-
tive first-morning urine samples were collected for the
analysis of albumine-to-creatinine ratio (ACR). Blood
samples after at least 10 h fasting were obtained to deter-
mine HbA1c (DCCT standardized), total cholesterol,
HDL cholesterol, triglycerides, Apolipoprotein A1, Apoli-
poprotein B, and lipoprotein (a) levels.
The cost associated to the continuous education pro-
gramme was determined by taking into account the
Structure of the clinical trial Figure 1
Structure of the clinical trial.BMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
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number of hours of sessions. According to Lain Entralgo
Agency the cost of 1-hour session was 72.5 € during 2003
and 2004 and 85 € during 2005 and 2006. In total 312
hours sessions were carried out during the study.
The statistical study was performed by using the SPSS 12.0
program for windows. Descriptive data are expressed as
median and quartiles 25 and 75 for describing the studied
variables. Parametric, one-way analysis of variance and
non-parametric Mann-Whitney and Kruskall-Wallis tests
to determine whether there are significant differences
between two or more independent groups were carried
out.
Results
The median of clinical and laboratory data change at entry
and during follow-up were similar among diabetic
patients assigned to be treated by the diabetes team
(Group A) or by family physicians (Group B) and differ-
ences between groups were not found (table 2). A signifi-
cant trend to reduce the medians of the blood pressure
values (SBP, -10 mm Hg in Group A and B; DBP – 4 mm
Hg in Group A and 7 mm Hg in Group B, respectively),
total cholesterol (Group A, 181 vs. 148 mg/dl and Group
B, 189 vs160 mg/dl, respectively) and LDL cholesterol lev-
els from 104 to 78 mg/dl (Group A) and from 107 to 81
mg/dl (Group B) were observed in both groups (all p <
0.05). No significant changes in clinical data including
BMI, waist circumference, HbA1c, and albumine-to-creat-
inine ratio values and triglycerides and HDL cholesterol
levels were found. The percentage of diabetic patients
achieving the blood pressure (SBP: from 21 and 24% to
51 and 43% and DBP: from 53 and 46% to 82 and 86%
for Group A and B, respectively), total cholesterol (Group
A, 68 vs. 93%; Group B 68 vs. 95%) and LDL cholesterol
(Group A, 46 vs. 84%; Group B, 39 vs. 78%) targets
increases during the follow-up, whereas glycemic control
and triglycerides and HDL-cholesterol levels were simi-
larly maintained in both groups. In addition, BMI
(slightly greater in group B as compared with group A, p <
0.05) and waist circumference remain unchanged in both
groups and the number of actual smokers and anti-aggre-
gated subjects were similar in both groups. When these
figures were compared between group A and B, differences
were only found in BMI change (p < 0.05). Data are dis-
played in table 3.
In total 4 three-days meetings, one a year (96 hours in
total) and 36 three-days 2-hours sessions (216 hours in
total), nine a year, were carried out between 2003 and
2006. The excess of cost associated with the programme
was estimated in 25,570 €, 6,392.5 € a year.
Discussion
Cardiovascular events remain the first cause of death in
people with diabetes, and multifactorial treatment is the
cornerstone to improve outcomes. Treatment of type 2
diabetic patients is mainly provided by the FP. Data in this
study suggest that the impact on metabolic outcomes of
continuous coordination between FP and the specialized
diabetes team allows diabetic patients treated in the pri-
mary care setting to obtain similar levels of ATP III treat-
ment and Steno goals than diabetic patients treated by a
specialized diabetes team. More than 75% diabetic
patients with peripheral vascular disease treated at pri-
mary health care level achieved adequate targets for
diastolic blood pressure, cholesterol, LDL-cholesterol and
triglycerides levels (also apolipoprotein B values). Also
more than 35% of patients reached Hb1c level < 6.5%,
and most of the patients were anti-aggregated. These fig-
ures were maintained at the end of follow up. In addition,
there were no differences between these outcomes and
those of the patients treated exclusively in the endocrinol-
ogy service. These percentages of patients in low-risk val-
ues are similar to that reported for patients treated by the
Diabetes team in the Steno study. However in our study,
twice the percentage of patients achieved an HbA1c <
6.5% compared with the Steno group, similar that
reported in specialized centres in Spain [16,17], and sig-
nificantly greater than the reported in primary health set-
tings in Spain, including diabetic patients at low-risk [10-
Table 1: Characteristic of the survey population by group
Group A Group B
N (Men/Women) 57 (43/14) 59 (39/20)
Age (yr.) 69 (58–74) 70 (57–76)
Duration of disease (yr) 19 (10–26) 19 (10–28)
Diabetes complications n (%)
Diabetic retinopathy 35 (61) 33 (56)
Diabetic neuropathy 44 (77) 47 (80)
Diabetic nephropathy 26 (46) 33 (56)
Diabetes Treatment n (%)
Oral agents 18 (32) 20 (34)
Insulin 41 (72) 37 (63)
Lipid lowering Treatment n (%)
Statins 44 (77) 35 (59)
Fibrates 2 (4) 7 (12)
Antihypertensive treatment n (%)
ACE inhibitors or ARA II 51 (88) 46 (78)
3 or more drugs 7 (12) 11 (19)
Antiaggregation n (%) 50 (88) 53 (90)
Actual smokers n (%) 11 (19) 11 (19)
Inclusion criteria n (%)
Arterial reconstruction 27 (47) 30 (51)
Foot ulcer 16 (28) 12 (20)
ABI < 0.8 14 (25) 17 (29)
Group A, diabetic patients treated by endocrinology service. Group 
B, diabetic patients treated by coordinated team, Family Physicians 
(FP) and endocrinologist, at primary care site.
Data expressed as median (Q1–Q3) or n (%).
ABI, ankle-brachial index. ACE, angiotensin convert enzyme ARA II, 
angiotensin II-receptor antagonist.BMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
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15] and high-risk [21]. Similarly, the achievement of the
ADA recommendations among US adults in clinical prac-
tice is no better than in the current study [23].
After the Steno 2 results [3], is well recognized that the
management of patients in high-risk must simultaneously
involve glycemic control as well as other cardiovascular
risk factors. However FP may adopt extremely heterogene-
ous management strategies and many DPts may remain
undertreated. In addition, the situation of FP in Spain is
usually unstable and frequently change their work place,
being an additional barrier to effective care. Along the
duration of the present study 234 FP (77%) changed their
work place. Usually, diabetic patients followed by differ-
ent FP in the same health care centre show a risk of inad-
equate metabolic control similar to that of diabetic
patients followed by FP adopting a non-aggressive policy.
However, our data do not support that, showing that a
primary-secondary interacted care as designed in our area
may result in better clinical outcomes in terms of meta-
bolic control. Considering that the vast majority of dia-
betic patients should be treated and followed at the
primary health care level, several strategies were designed
[24]. In order to improve patients outcomes, physicians-
centered educational activities to increase the awareness
of the potential benefits of a tight multifactorial control
Table 2: Clinical and Laboratory data for the diabetic subjects during treatment period by Group
Baseline 6 12 18 24 30 months
BMI (Kg.m-2)
- Group A 28 (25–31) 28 (25–32) 28 (25–32) 28 (25–32) 28 (26–32) 28 (25–32)
- Group B 29 (27–34) 30 (27–32)& 30 (27–33)& 30 (27–32)& 30 (28–36)& 30 (27–35)&
Waist Circumference(cm)
- Group A
Men 103 (96–109) 104 (98–109) 102 (97–108) 102 (92–109) 103 (97–109) 103 (97–112)
Women 100 (88–114) 96 (87–113) 95 (86–110) 98 (81–113) 99 (81–114) 98 (80–115)
-Group B
Men 103 (99–113) 106 (98–115) 106 (98–113)& 103 (99–114) 103 (98–111) 104 (95–118)
Women 100 (89–114) 104 (84–118)& 110 (83–128)& 107 (82–125)& 101 (78–127) 99 (79–126)
SBP mm Hg
- Group A 140 (135–155) 137 (130–144) 135 (125–144)* 135 (125–145)* 135 (125–144)* 130 (125–135)**
- Group B 145 (132–160) 138 (128–150)* 135 (127–150)* 132 (125–144)** 135 (125–145)** 135 (121–147)*
DBP mm Hg
- Group A 80 (75–87) 76 (70–80)* 75 (70–80)* 78 (70–80) 78 (70–80) 76 (71–80)*
- Group B 85 (76–90) 79 (70–84) * 78 (71–80)* 77 (70–79)* 77 (69–78)* 78 (68–79)*
HbA1c (%)
- Group A 7.2 (6.5–8.5) 7.0 (6.6–7.9) 7.0 (6.6–7.8) 6.9 (6.4–7.8) 7.1 (6.4–7.9) 7.3 (6.5–7.9)
- Group B 7.5 (6.5–9.2) 7.3 (6.3–8.2) 7.4 (6.4–8.0) 7.0 (6.3–8.2)* 7.3 (6.4–8.0) 7.1(6.4–8.3)*
ACR (mg/g)
- Group A 22 (8–145) 20 (8–99) 22 (9–66) 15 (9–76) 19 (8–86) 27 (9–97)
- Group B 25 (7–128) 29 (10–137) 25 (8–135) 25 (8–141) 20 (11–105) 25 (9–158)
Total Cholesterol (mg/dl)
- Group A 181 (158–208) 165 (151–182)* 165 (150–183)* 155 (135–175)* 154 (129–166)* 148 (135–163)**
- Group B 189 (164–217) 167 (151–200)* 170 (147–185)* 159 (141–178)** 158 (132–182)** 160 (143–185) **
HDL-Cholesterol (mg/dl)
-Group A
Men 46 (41–55) 46 (43–56) 50 (43–57) 50 (43–56) 46 (40–54) 48 (40–55)
Women 55 (48–65) 59 (51–71) 58 (49–65) 64 (50–66) 63 (56–68) 56 (54–64)
-Group B
Men 49 (39–54) 49 (42–55) 50 (44–53) 50 (43–54) 50 (47–55) 50 (45–55)
Women 50 (42–60) 53 (45–64) 45 (43–58) 48 (42–58) 48 (37–55) 52 (43–57)
LDL-Cholesterol (mg/dl)
- Group A 104 (87–128) 93 (83–107) 88 (75–104)* 77 (66–95)** 75 (64–94)** 78 (69–86)**
- Group B 107 (87–136) 96 (78–112)* 91 (77–109)* 82 (72–99)** 80 (64–98)** 81 (70–97) **
Triglycerides (mg/dl)
- Group A 102 (85–145) 98 (74–149) 112 (77–139) 108 (71–138) 100 (80–141) 97 (75–137)
- Group B 119 (86–160) 105 (87–160) 109 (80–160) 116 (79–158) 117 (79–152) 105 (79–150)
Group A, diabetic patients treated by endocrinology service. Group B, diabetic patients treated by coordinated team, FP and endocrinologist, at 
primary care site. Data expressed as median (Q1–Q3).
BMI, body mass index. SBP, Systolic Blood Pressure. DBP, Diastolic Blood Pressure. ACR, albumine-to-creatinine ratio.
*p < 0.05, ** p < 0.01, denote differences in relation to baseline values. &p < 0.05 denote differences between Group A vs. Group B.BMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
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were applied in our study. At the beginning, patients were
treated by endocrinologists as usually during a 3–6
months period, in order to adapt the pharmacological
treatment and behaviour modification at least every 2 to
4 weeks, and then by family physicians. However, family
physicians and endocrinologists were continuously in
Table 3: Number (%) of DPts on Targets of Metabolic Control according to ATP-III Panel and Steno Study
B a s e l i n e 6 1 21 82 4 3 0  m o n t h s
HbA1c < 7%:
- Group A 25 (44) 31 (55) 32 (56) 34 (60) 28 (49) 24 (42)
- Group B 19 (33) 22 (37) 27 (46) 31 (53) 25 (43) 27 (46)
HbA1c < 6.5%:
- Group A 16 (28) 14 (25) 13 (23) 21 (37) 17 (30) 21 (37)
- Group B 15 (26) 16 (27) 18 (30) 24 (41) 22 (37) 22 (37)
SBP < 130 mm Hg:
- Group A 12 (21) 21 (37) 24 (42)* 22 (39)* 23 (41)* 29 (51)*
- Group B 14 (24) 17 (29) 28 (48)* 28 (48)* 24 (41)* 25 (43)*
DBP < 80 mm Hg:
- Group A 30 (53) 44 (77) 49 (86)* 44 (77) 45 (79)* 47 (82)*
- Group B 27 (46) 44 (75) 50 (85)* 53 (90)* 53 (90)* 51 (86)*
Cholesterol < 200 mg/dl:
- Group A 39 (68) 50 (88)* 51 (90)* 48 (84)* 54 (95)* 53 (93)*
- Group B 40 (68) 45 (76)* 48 (81)* 52 (88)* 55 (93)* 56 (95)*
Triglycerides < 150 mg/dl:
- Group A 44 (77) 44 (77) 48 (84) 48 (84) 47 (82) 50 (88)
- Group B 45 (76) 40 (68) 42 (71) 43 (73) 45 (76) 48 (81)
HDL cholesterol (mg/dl)
Men > 40:
- Group A 33 (77) 33 (77) 37 (86) 39 (91) 32 (74) 30 (70)
- Group B 28 (72) 31 (80) 31 (80) 31 (80) 30 (77) 34 (87)
Women > 50:
- Group A 9 (64) 11 (79) 10 (71) 10 (71) 12 (86) 12 (86)
- Group B 10 (50) 12 (60) 9 (45) 8 (40) 8 (40) 11 (55)
LDL cholesterol < 100 mg/dl:
- Group A 26 (46) 41 (72)* 38 (67)* 44 (77)* 50 (88)** 48 (84)**
- Group B 23 (39) 33 (56)* 37 (63)* 46 (78)* 51 (86)** 46 (78)**
Apolipoprotein B < 100 mg/dl:
- Group A 32 (56) 45 (79)* 48 (84)* 48 (84)* 52 (91)* 53 (93)*
- Group B 27 (46) 42 (71)* 42 (71)* 51 (86)* 50 (85)* 50 (85)*
BMI < 25 Kg.m-2:
- Group A 13 (23) 12 (21) 11 (19) 13 (23) 12 (21) 13 (23)
- Group B 5 (9)& 5 (9)& 5 (9)& 9 (15)& 7 (12)& 7 (12)&
Waist Circumference
Men < 102 cm:
- Group A 21 (49) 18 (42) 22 (51) 23 (53) 20 (47) 20 (47)
- Group B 17 (44) 18 (46) 16 (41)& 19 (49) 19 (49) 19 (49)
Women < 88 cm:
- Group A 3 (21) 4 (29) 5 (36) 4 (29) 4 (29) 4 (29)
- Group B 4 (20) 5 (25) 5 (25) 6 (30) 6 (30) 6 (30)
ACR < 30 mg/g:
- Group A 31 (54) 32 (56) 32 (56) 34 (60) 29 (51) 29 (51)
- Group B 26 (44) 30 (51) 27 (46) 31 (53) 25 (42) 30 (51)
Current smokers:
- Group A 11 (19) 8 (14) 8 (14) 7 (12) 7 (12) 7 (12)
- Group B 11 (19) 8 (14) 7 (12) 7 (12) 7 (12) 7 (12)
Antiaggregated treatment:
- Group A 50 (88) 50 (88) 50 (88) 50 (88) 50 (88) 50 (88)
- Group B 53 (90) 53 (90) 53 (90) 53 (90) 53 (90) 53 (90)
Group A, diabetic patients treated by endocrinology service. Group B, diabetic patients treated by coordinated team, Family Physician and 
endocrinologist, at primary care site.
SBP, systolic blood pressure. DBP, diastolic blood pressure. BMI, body mass index. ACR, albumine-to-creatinine ratio.
*p < 0.05, ** p < 0.01, denote differences in relation to baseline values. &p < 0.05, denote differences between Group A vs. Group B.BMC Endocrine Disorders 2008, 8:9 http://www.biomedcentral.com/1472-6823/8/9
Page 8 of 9
(page number not for citation purposes)
contact. Guidelines for multifactorial intervention were
the same for both FP and endocrinologists. Continuous
formative evaluation of diabetes teaching and treatment
goals has been reported as essential [25], as considered in
our programme. Training and coordination of clinical
programmes with FP are included in the specialist con-
sultant's job description. According to data reported in
this study, the levels of most of the therapeutic targets
remained stable or improved during the follow-up, in a
similar way in both groups of patients. In order to
improve the programme and to identify possible causes of
failure and inertia, several strategies were developed. A
continuous exchange of information between FP and
endocrinologists was established across face to face meet-
ings, mail or phone contact. It is quite likely that the
results obtained in the present study have been favourably
influenced by this coordination between medical and
educators teams.
The aim of treatment of overweight type 2 diabetic
patients must be reduction of body weight as well as other
cardiovascular risk factors. Despite the improvement in
cardiovascular risk factors, control of body weight
remains inadequate as previously reported by our group
[26]. Possibly, both FP and specialized physicians give
greater priority to the control of other metabolic factors
because these patients present greater difficulty in losing
weight compared to diabetic subjects without peripheral
vascular disease, thus implying the need for pharmacolog-
ical treatment. In Spain, the National Health System cov-
ers between 75% and 100% of the cost of the
pharmacological treatments when prescribed by physi-
cians. Sibutramine and orlistat are excluded and have to
be paid by the patients. In our study none received anti
obesity drugs. In addition, educational programmes using
behaviour modification are useful to induce weight reduc-
tion, as our group previously reported [26], but physical
exercise remains as the main long-term predictor for
weight loss [27], and DPts with PVD have a reduced exer-
cise capacity. Surgical procedures in Spain is not consid-
ered when BMI < 40 Kg.m-2, as our patients.
The present study findings are potentially important
because the management of type 2 diabetic patients in
Spain is mainly provided by the FP. When targets of dia-
betes treatments are not reached, diabetic patients should
be derived to the specialized level. Nevertheless, this
measure is usually taken too late. To avoid this failure, in
Area 7 of Madrid a system of immediate communication
through phone, mail or face to face is available. In addi-
tion, periodic meetings with health care teams and their
leaders have been established. The diabetes programme in
Area 7 of Madrid defines how diabetes management
should be more that who is responsible for it. In our pat-
tern, care of diabetes mellitus should be shared between
FP and the diabetes team. The success of this strategy
relays in guaranteeing a continuous communication
between both FP and the diabetes team. FP had full access
to nurse specialists in foot programme and diabetes edu-
cation, dietitians and podiatry depending on the foot
unit. The decrease in the clinical burden in the specialized
level translates in more availability for clinical research
and for assistance of clinical complex cases. Training and
coordination of clinical programmes with FP are included
in the endocrinologist consultant's job description, with-
out to increase the resources. As to the economic cost, the
two hours-sessions and the three days annual meetings,
were taken into account to estimate the extraordinary
expenses. Therefore, according to data obtained in the cur-
rent study, we may consider that this programme of con-
tinuous education is efficient.
Conclusion
In summary, our results show that a training and contin-
uous communication between primary care and endo-
crinology is possible in clinical practice and results in
benefits in terms of health care and cardiovascular risk fac-
tors control, with an appropriate use of personal
resources. A reduction in diabetes complications as well as
cardiovascular events will be expected.
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